Effect of granulocyte macrophage-colony stimulating factor on extracellular matrix deposition by dermal fibroblasts from patients with scleroderma

Journal of Rheumatology

Volumn 32, Issue 4, 2005, Pages 656-664

  Postiglione, Loredana ^a   Ladogana, Paolo ^a   Montagnani, Stefania ^a   Di Spigna, Gaetano ^a   Castaldo, Clotilde ^a   Turano, Mimmo ^b   Bruno, Eugenia Maria ^a   Di Meglio, Franca ^a   Riccio, Antonio ^a   Rossi, Guido ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Grande Ospedale Metropolitano   (Italy)

Author keywords

Extracellular matrix; Fibroblasts; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor receptor; Systemic sclerosis

Indexed keywords

COLLAGEN TYPE 1; COLONY STIMULATING FACTOR RECEPTOR; FIBRONECTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERSTITIAL COLLAGENASE; MESSENGER RNA; TENASCIN;

ADULT; AGED; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; PATIENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN CULTURE; SYNDROME CREST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ADULT; AGED; CELLS, CULTURED; COLLAGEN TYPE I; CREST SYNDROME; DERMIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RNA, MESSENGER; SCLERODERMA, DIFFUSE; TENASCIN;

EID: 20244376007     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chen K, See A, Shumack S. Epidemiology and pathogenesis of scleroderma. Australas J Dermatol 2003;44:1-7.
2. Medsger TA. Comment on scleroderma criteria cooperative study. Black CM, Myers AR, editors. Current topics in rheumatology. New York: Gower Medical Publishing; 1985.
3. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosic (sceroderma). Clin Rheum Dis 1979;5:5.
4. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988;15:202-5.
5. Denton CP, Xu S, Black CM, Pearson JD. Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. J Invest Dermatol 1997;108:269-74.
6. Needlemann BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
7. Patrick MR, Kirkhan BW, Graham M, Herrison LC. Circulating interleukin-lβ and soluble interleukin-2 receptor: evaluation as markers of disease activity in scleroderma. J Rheumatol 1995;22:654-9.
8. Umehara H, Kumagai S, Ishida H, Suginoshita T, Maeda K, Imura H. Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells? Arthritis Rheum 1988;31:401-7.
9. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2000;24:560-9.
10. Inagaki Y, Truter S, Ramirez F. Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an SpI-binding site. J Biol Chem 1994;269:14828-34.
11. Riccio A, De Caterina M, Natale D, et al. Serum levels of granulocyte macrophage-colony stimulating factor (GM-CSF) in a group of patients with systemic sclerosis. Int J Immunopathol Pharmacol 1996;9:9-12.
12. Dedhar S, Gaboury L, Galloway P, Eaves C. Human GM-CSF is a growth factor active on variety of cell types of non-hemopoietic origin. Proc Natl Acad Sci USA. 1988;85:9253-7.
13. Metcalf D. The GM-CSF. Science 1985;229:16-23.
14. Aglietta M, Monzeglio C, Sanavio F, et al. In vivo effect of human GM-CSF on megakaryocytopoiesis. Blood 1991;77:1191-4.
15. Gasson JC. Molecular physiology of GM-CSF. Blood 1991;77:1131-9.
16. Bussolino F, Ziche X, Ming Wang J, et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest 1991;87:986-93.
17. Lang RA, Cuthbertson RA, Kelso A, et al. Transgenic mice expressing a hematopoietic growth factor gene (GM-CSF) develop accumulation of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1997;51:675-88.
18. Postiglione L, Montagnani S, Riccio A, et al. Enhanced expression of the receptor for granulocyte macrophage-colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol 2002;29:94-101.
19. Colotta F, Bussolino F, Polentarutti N, et al. Differential expression of the common β and specific α chains of the receptors for GM-CSF, IL3 and IL5 endothelial cells. Cell Res 1993;206:311-20.
20. Steen VD, Medsger TA Jr, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652-9.
21. Liu T, Dhanasekaran SM, Jin H, et al. FIZZ 1 stimulation of myofibroblast differentiation. Am J Pathol 2004;164:1315-26.
22. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996;39:1338-46.
23. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor β1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-88.
24. Yamane K, Ihn H, Kubo M, Tamaki K. Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts. Arthritis Rheum 2002;46:2421-8.
25. Postiglione L, Montagnani S, Riccio A, et al. Expression of GM-CSF receptor and "in vitro" effects of GM-CSF on human fibroblasts. Life Sci 1998;63:327-36.
26. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994;94:2489-92.
27. Rosenbloom J, Feldman G, Freundlich B, Jimenez SA. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 1986;29:851-6.
28. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994;103:359-63.
29. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567-72.
30. Kuroda K, Tsukifuji R, Shinkai H. Increased expression of heat-shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. J Invest Dermatol 1998;111:1023-8.
31. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253-64.
32. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001;14:10594-601.
33. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78.
34. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J. Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003;121):41-50.
35. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002;227:301-14.
36. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin αvβ5 on scleroderma fibroblasts. Am J Pathol 2004;164:1275-92.
37. Jorgensen LN, Agren MS, Madsen SM, et al. Dose-dependent impairment of collagen deposition by topical granulocyte macrophage colony stimulating factor in human experimental wounds. Ann Surg 2002;236:684-92.